Sema Kurtuluş

3.6k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Sema Kurtuluş is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Sema Kurtuluş has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 11 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Sema Kurtuluş's work include Immune Cell Function and Interaction (12 papers), Immunotherapy and Immune Responses (9 papers) and T-cell and B-cell Immunology (9 papers). Sema Kurtuluş is often cited by papers focused on Immune Cell Function and Interaction (12 papers), Immunotherapy and Immune Responses (9 papers) and T-cell and B-cell Immunology (9 papers). Sema Kurtuluş collaborates with scholars based in United States, Türkiye and Australia. Sema Kurtuluş's co-authors include Ana C. Anderson, Mark J. Smyth, William C. Dougall, Vijay K. Kuchroo, David A. Hildeman, Orit Rozenblatt–Rosen, Aviv Regev, Junrong Xia, Jackson Nyman and Pulak Tripathi and has published in prestigious journals such as Cell, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Sema Kurtuluş

22 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

2019 401 citations Sema Kurtuluş, Asaf Madi et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sema Kurtuluş United States	13	1.3k	970	313	97	87	23	1.7k
Junrong Xia United States	6	1.6k 1.2×	842 0.9×	304 1.0×	81 0.8×	104 1.2×	6	2.0k
Sonia Pastor France	14	946 0.7×	857 0.9×	229 0.7×	71 0.7×	107 1.2×	22	1.4k
Victor Levitsky Sweden	17	1.1k 0.8×	627 0.6×	313 1.0×	82 0.8×	116 1.3×	37	1.5k
Ornella Pagliano United States	9	1.3k 0.9×	1.2k 1.3×	206 0.7×	58 0.6×	59 0.7×	17	1.6k
Victor H. Salinas United States	6	1.2k 0.9×	989 1.0×	308 1.0×	80 0.8×	97 1.1×	12	1.8k
Jorge A. García United States	11	1.4k 1.0×	714 0.7×	268 0.9×	99 1.0×	94 1.1×	19	1.7k
Sinisa Ivelja United States	5	994 0.7×	736 0.8×	184 0.6×	64 0.7×	75 0.9×	5	1.3k
Remko Schotte Netherlands	14	1.4k 1.0×	923 1.0×	468 1.5×	89 0.9×	65 0.7×	23	1.8k
Estelle Devêvre Switzerland	17	1.5k 1.1×	918 0.9×	344 1.1×	92 0.9×	187 2.1×	26	1.8k
Noweeda Mirza United States	10	1.1k 0.8×	819 0.8×	377 1.2×	68 0.7×	116 1.3×	16	1.5k

Countries citing papers authored by Sema Kurtuluş

Since Specialization

Citations

This map shows the geographic impact of Sema Kurtuluş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sema Kurtuluş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sema Kurtuluş more than expected).

Fields of papers citing papers by Sema Kurtuluş

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sema Kurtuluş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sema Kurtuluş. The network helps show where Sema Kurtuluş may publish in the future.

Co-authorship network of co-authors of Sema Kurtuluş

This figure shows the co-authorship network connecting the top 25 collaborators of Sema Kurtuluş. A scholar is included among the top collaborators of Sema Kurtuluş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sema Kurtuluş. Sema Kurtuluş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Molony, Ryan D., Gina M. Trabucco, Erik Corcoran, et al.. (2022). CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses. Frontiers in Immunology. 13. 909979–909979. 3 indexed citations

Wang, Hui Qin, Iain J. Mulford, Fiona A. Sharp, et al.. (2021). Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Research. 81(11). 3079–3091. 43 indexed citations

Kurtuluş, Sema, et al.. (2019). Organik Ürün Tüketicilerinin Tipolojisi: Gönüllü Sadelik, Çevre Bilinci ve Değerler Açısından Pazar Bölümlerinin İncelenmesi. 11(1). 107–142. 2 indexed citations

Kurtuluş, Sema, Asaf Madi, Giulia Escobar, et al.. (2019). Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells. Immunity. 50(1). 181–194.e6. 401 indexed citations breakdown →

Ladle, Brian H., et al.. (2019). T-cell receptor signal strength and epigenetic control of Bim predict memory CD8+ T-cell fate. Cell Death and Differentiation. 27(4). 1214–1224. 19 indexed citations

Conlon, Kevin C., Rom S. Leidner, Douglas G. McNeel, et al.. (2019). Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors. Cancer Research. 79(13_Supplement). CT082–CT082. 2 indexed citations

Conlon, Kevin C., Rom S. Leidner, Douglas G. McNeel, et al.. (2019). Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors. Clinical Trials. CT082–CT082. 1 indexed citations

Kurtuluş, Sema, et al.. (2018). Tüketicilerin Fiyat Taktiklerinin İkna Kabiliyeti İle İlgili Bilinç Düzeyi Ölçeğinin Türkçeye Uyarlanması. 4(1). 65–78. 1 indexed citations

Dixon, Karen O., Michelle Schorer, James Nevin, et al.. (2018). Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. The Journal of Immunology. 200(8). 3000–3007. 133 indexed citations

10.

Dougall, William C., Sema Kurtuluş, Mark J. Smyth, & Ana C. Anderson. (2017). TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews. 276(1). 112–120. 350 indexed citations

11.

Singer, Meromit, Chao Wang, Le Cong, et al.. (2016). A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell. 166(6). 1500–1511.e9. 269 indexed citations

12.

Kurtuluş, Sema, et al.. (2016). SOSYAL OLAYLARIN SİYASAL MARKA KİŞİLİĞİ ÜZERİNDEKİ YANSIMALARI. DergiPark (Istanbul University). 37(2). 285–285.

13.

Overacre-Delgoffe, Abigail E., Sema Kurtuluş, Mario Sznol, et al.. (2015). Combination immunotherapy: Where do we go from here?. Journal for ImmunoTherapy of Cancer. 3(1). 2 indexed citations

14.

Kurtuluş, Sema, Pulak Tripathi, & David A. Hildeman. (2013). Protecting and rescuing the effectors: roles of differentiation and survival in the control of memory T cell development. Frontiers in Immunology. 3. 404–404. 31 indexed citations

15.

Kurtuluş, Sema & David A. Hildeman. (2013). Assessment of CD4+ and CD8+ T Cell Responses Using MHC Class I and II Tetramers. Methods in molecular biology. 979. 71–79. 10 indexed citations

16.

Ligons, Davinna L., Ceren Tuncer Şakar, Sema Kurtuluş, et al.. (2012). CD8 Lineage-specific Regulation of Interleukin-7 Receptor Expression by the Transcriptional Repressor Gfi1. Journal of Biological Chemistry. 287(41). 34386–34399. 17 indexed citations

17.

Kurtuluş, Sema, Pulak Tripathi, Maria E. Moreno‐Fernandez, et al.. (2011). BCL-2 allows effector and memory CD8+ T cells to tolerate higher expression of BIM (104.19). The Journal of Immunology. 186(1_Supplement). 104.19–104.19. 2 indexed citations

18.

Kurtuluş, Sema, Pulak Tripathi, Joseph T. Opferman, & David A. Hildeman. (2010). Contracting the ‘mus cells’– does down‐sizing suit us for diving into the memory pool?. Immunological Reviews. 236(1). 54–67. 27 indexed citations

19.

Tripathi, Pulak, Sema Kurtuluş, Sara Wojciechowski, et al.. (2010). STAT5 Is Critical To Maintain Effector CD8+ T Cell Responses. The Journal of Immunology. 185(4). 2116–2124. 90 indexed citations

20.

Guimond, Martin, Rachelle G. Veenstra, David J. Grindler, et al.. (2009). Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nature Immunology. 10(2). 149–157. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact